|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. FIGO 26th annual report on the results of
treatment in gynecological cancer. Int J Gynaecol Obstet. 95 Suppl
1:161–192. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Niikura T, Hashimoto Y, Tajima H, Ishizaka
M, Yamagishi Y, Kawasumi M, Nawa M, Terashita K, Aiso S and
Nishimoto I: A tripartite motif protein TRIM11 binds and
destabilizes Humanin, a neuroprotective peptide against Alzheimers
disease-relevant insults. Eur J Neurosci. 17:1150–1158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hong SJ, Chae H, Lardaro T, Hong S and Kim
KS: Trim11 increases expression of dopamine beta-hydroxylase gene
by interacting with Phox2b. Biochem Biophys Res Commun.
368:650–655. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tuoc TC and Stoykova A: Trim11 modulates
the function of neurogenic transcription factor Pax6 through
ubiquitin-proteosome system. Genes Dev. 22:1972–1986. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishikawa H, Tachikawa H, Miura Y and
Takahashi N: TRIM11 binds to and destabilizes a key component of
the activator-mediated cofactor complex (ARC105) through the
ubiquitin-proteasome system. FEBS Lett. 580:4784–4792. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di K, Linskey ME and Bota DA: TRIM11 is
overexpressed in high-grade gliomas and promotes proliferation,
invasion, migration and glial tumor growth. Oncogene. 32:5038–5047.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang X, Shi W, Shi H, Lu S, Wang K, Sun C,
He J, Jin W, Lv X, Zou H and Shu Y: TRIM11 overexpression promotes
proliferation, migration and invasion of lung cancer cells. J Exp
Clin Cancer Res. 35:1002016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin Y, Zhong J, Li S-W, Li JZ, Zhou M,
Chen Y, Sang Y and Liu L: TRIM11, a direct target of miR-24-3p,
promotes cell proliferation and inhibits apoptosis in colon cancer.
Oncotarget. 7:86755–86765. 2016.PubMed/NCBI
|
|
11
|
Sakuma M, Akahira J, Suzuki T, Inoue S,
Ito K, Moriya T, Sasano H, Okamura K and Yaegashi N: Expression of
estrogen-responsive finger protein (Efp) is associated with
advanced disease in human epithelial ovarian cancer. Gynecol Oncol.
99:664–670. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma Y, Wei Z, Bast RC Jr, Wang Z, Li Y, Gao
M, Liu Y and Wang X, Guo C, Zhang L and Wang X: Downregulation of
TRIM27 expression inhibits the proliferation of ovarian cancer
cells in vitro and in vivo. Lab Invest. 96:37–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Santin AD, Zhan F, Bellone S, Palmieri M,
Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, et al:
Gene expression profiles in primary ovarian serous papillary tumors
and normal ovarian epithelium: identification of candidate
molecular markers for ovarian cancer diagnosis and therapy. Int J
Cancer. 112:14–25. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tan H, Liu Z, Qi J and Chu G: Tripartite
motif 16 inhibits the migration and invasion in ovarian cancer
cells. Oncol Res. 25:551–558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reed JC: Regulation of apoptosis by bcl-2
family proteins and its role in cancer and chemoresistance. Curr
Opin Oncol. 7:541–546. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leber MF and Efferth T: Molecular
principles of cancer invasion and metastasis (Review). Int J Oncol.
34:881–895. 2009.PubMed/NCBI
|
|
17
|
Davidson B, Goldberg I, Gotlieb WH,
Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M and Reich
R: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate
with poor survival in ovarian carcinoma. Clin Exp Metastasis.
17:799–808. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Downward J: PI 3-kinase, Akt and cell
survival. Semin Cell Dev Biol. 15:177–182. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boucher MJ, Morisset J, Vachon PH, Reed
JC, Lainé J and Rivard N: MEK/ERK signaling pathway regulates the
expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of
human pancreatic cancer cells. J Cell Biochem. 79:355–369. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jung C-H, Kim EM, Park JK, Hwang SG, Moon
SK, Kim WJ and Um HD: Bmal1 suppresses cancer cell invasion by
blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway.
Oncol Rep. 29:2109–2113. 2013.PubMed/NCBI
|
|
21
|
Adya R, Tan BK, Punn A, Chen J and Randeva
HS: Visfatin induces human endothelial VEGF and MMP-2/9 production
via MAPK and PI3K/Akt signalling pathways: novel insights into
visfatin-induced angiogenesis. Cardiovasc Res. 78:356–365. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morgensztern D and McLeod HL:
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer
Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kohno M and Pouyssegur J: Targeting the
ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hill MM and Hemmings BA: Inhibition of
protein kinase B/Akt. implications for cancer therapy. Pharmacol
Ther. 93:243–251. 2002. View Article : Google Scholar : PubMed/NCBI
|
